FDA warns J & J on insulin pumps

Share this article:

Johnson & Johnson could face penalties for not reporting incidents where insulin pumps have failed, the Food and Drug Administration has warned.

In a Dec. 27 letter to the company's Animas Corp. unit, the FDA says the company should have reported incidents where the device failure may have caused injury, including diabetic ketoacidosis. It also said Animas failed to create a system for making adequate medical device reports.

The letter, which was made public last week, followed a site visit in 2011. It warns “failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.”

Diabetes is among the top ten leading causes of death in the U.S. Insulin pumps deliver rapid- or short-acting insulin throughout the day via a catheter rather than require a person or caregiver to do periodic injections.



Share this article:

More in News

ACO bill in House would waive 3-midnight requirement for skilled nursing care

Certain Accountable Care Organizations would be able to send Medicare beneficiaries to a skilled nursing facility without a prior hospital stay under a bipartisan bill recently introduced in the House of Representatives.

Increasing staff-to-patient ratios improves nurse safety, researchers find

A law setting mandatory nurse-to-patient staffing ratios has reduced the number of workplace injuries for registered nurses and licensed practical nurses in California, according to recently published findings.

Life Care Centers takes Gold in Transitions category

Life Care Centers takes Gold in Transitions category

Life Care Centers of America has won the Gold Award in the McKnight's Excellence in Technology Awards in the Transitions category.